我要投票 保灵药业在中草药行业中的票数:72
· 外 推 电 报 ·
2025-02-05 18:49:29 星期三

【保灵药业是哪个国家的品牌?】

保灵药业是什么牌子?「保灵药业」是 杭州澳医保灵药业有限公司 旗下著名品牌。该品牌发源于浙江,由创始人钟海荣在1994-12-30期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

杭州保灵集团有限公司,成立于1985年,是国内较早从事蜂产品深度研究开发生产的企业。2013年8月,保灵集团正式牵手山西仟源制药股份有限公司。

澳医保灵成立于1994年,由保灵集团与澳大利亚、新加坡合资组建,注册资本为2882.47万元,位于杭州市保灵路5号,主要经营药品与原料药的生产工作。先后被评为杭州市高新技术企业及浙江省高新技术企业。

浙江保灵成立于2006年,由保灵集团与爱美雅(新加坡)有限公司合资组建,注册资本为8800万元,位于杭州经济技术开发区23号大街668号。一期总投资1.6亿元的现代化药品保健食品制造基地,于2010年12月投产。2013年12月,澳医保灵吸收合并浙江保灵。吸收合并后,浙江保灵于工商注销,澳医保灵注册资本为8800万元,注册地址为杭州经济技术开发区23号大街668号。

保灵药业主要从事药品、保健食品、蜂产品、植物提取物的研发、生产和销售。公司是国内著名的孕妇健康产品生产商和供应商,其系列产品包括保灵孕宝口服液、保灵孕妇钙咀嚼片、保灵孕多维片以及保胎无忧片、生乳片等,其中保灵孕宝口服液自1989年(与澳方合资前由中方公司生产)上市以来,深受广大医生和孕妇的喜爱,“怀孕了就喝保灵孕宝”,“保灵孕宝健康两代人”已经深入人心。公司还拥有抗过敏药物,国家二类新药---依巴斯汀片(商品名“思金”),治疗青光眼药物---醋甲唑胺片(商品名“尼目克司”)等市场优势品种。自1997年以来,“保灵”商标就被评为浙江省著名商标。

保灵药业视产品质量为企业的立足之本,更是企业对社会的一种责任。公司每年按销售额的一定比例拨出专项资金作为技术改造及新产品研发费用,不断引进国内外领先的先进生产研发设备,如高效液相色谱仪、红外分光光度计等等,提高工作效率,改善生产条件,确保了产品质量安全稳定。保灵药业是浙江省首批通过药品和保健食品GMP双认证的企业。

保灵药业拥有一支高素质的员工队伍。在现有员工中,各类专业技术人员的比例超过40%。公司非常重视企业文化建设,不断引进现代企业管理理念和方法。培育了“效率、效益、和谐发展”为特质的保灵文化,培养了具有“忠诚、友善、敬业、创新”精神的保灵人。在和谐的保灵大家庭中,广大员工视公司为家,涌现了包括全国劳模、省劳模在内的一大批优秀人才。近年来,公司先后被评为浙江省文明单位、杭州市模范集体、杭州市和谐劳动关系先进企业、浙江省先进技术企业,浙江省高新技术企业,省级研发中心,杭州市工业重点纳税企业。

英文翻译:Hangzhou Baoling Group Co., Ltd., founded in 1985, is one of the earliest domestic enterprises engaged in the in-depth research, development and production of bee products. In August 2013, Baoling group formally joined hands with Shanxi Qianyuan Pharmaceutical Co., Ltd. Founded in 1994 by Baoling group, Australia and Singapore, aowuling has a registered capital of 28.8247 million yuan and is located at No.5, Baoling Road, Hangzhou, mainly engaged in the production of drugs and APIs. It has been awarded as Hangzhou high tech enterprise and Zhejiang high tech enterprise successively. Zhejiang Baoling was founded in 2006 by Baoling group and aimiya (Singapore) Co., Ltd. with a registered capital of 88 million yuan, it is located at No. 668, No. 23 street, Hangzhou Economic and Technological Development Zone. The first phase of a modern pharmaceutical and health food manufacturing base with a total investment of 160 million yuan was put into production in December 2010. In December 2013, aomaling absorbed and merged with Zhejiang Baoling. After the merger, Zhejiang Baoling was cancelled by industry and commerce. The registered capital of aobaoling is 88 million yuan, and the registered address is No. 668, No. 23 street, Hangzhou Economic and Technological Development Zone. Baoling pharmaceutical is mainly engaged in the R & D, production and sales of drugs, health food, bee products and plant extracts. The company is a famous manufacturer and supplier of pregnant women's health products in China. Its series of products include baolingyunbao oral liquid, Baoling pregnant women's calcium chewable tablets, baolingyun multi-dimensional tablets, baofetal worry free tablets, raw milk tablets, etc., among which baolingyunbao oral liquid has been popular with doctors and pregnant women since it was launched in 1989 (before the joint venture with Australia, it was produced by a Chinese company), and "drink when pregnant" "Baoling pregnant treasure" and "Baoling pregnant treasure healthy two generations" have been deeply rooted in people's hearts. The company also has anti allergy drugs, national class II new drugs - ebastine tablets (trade name "sikin"), glaucoma drugs - acetazolamide tablets (trade name "nemex") and other market advantages. Since 1997, "Baoling" trademark has been awarded as a famous trademark in Zhejiang Province. Baoling pharmaceutical regards product quality as the foundation of the enterprise, and it is also a responsibility of the enterprise to the society. According to a certain proportion of the sales volume, the company allocates special funds every year as the cost of technological transformation and new product research and development, and constantly introduces advanced production and research and development equipment at home and abroad, such as high-performance liquid chromatograph, infrared spectrophotometer, etc., to improve work efficiency, improve production conditions, and ensure the safety and stability of product quality. Baoling pharmaceutical is one of the first enterprises in Zhejiang Province to pass the GMP double certification of drugs and health food. Baoling pharmaceutical has a high-quality staff. In the existing staff, the proportion of all kinds of professional and technical personnel is more than 40%. The company attaches great importance to the construction of enterprise culture and constantly introduces modern enterprise management concepts and methods. It has cultivated a spirit preserving culture characterized by "efficiency, efficiency and harmonious development", and a spirit of "loyalty, friendliness, dedication and innovation". In the harmonious Baoling family, the majority of employees regard the company as their home, and a large number of outstanding talents including national and provincial model workers have emerged. In recent years, the company has been rated as a civilized unit in Zhejiang Province, a model collective in Hangzhou, an advanced enterprise in harmonious labor relations in Hangzhou, an advanced technology enterprise in Zhejiang Province, a high-tech enterprise in Zhejiang Province, a provincial R & D center, and a key industrial tax paying enterprise in Hangzhou.

本文链接: https://www.waitui.com/brand/940fa6127.html 联系电话:057188144888

千城特选小程序码

7×24h 快讯

慈星股份:终止筹划购买武汉敏声控股权并配套募资事项,股票明起复牌

36氪获悉,慈星股份公告,公司因筹划发行股份及支付现金购买武汉敏声新技术有限公司控股权并募集配套资金事项,公司股票自2025年1月15日开市时起开始停牌。经交易相关方商讨研究决定终止筹划本次交易事项,公司股票将于2025年2月6日(星期四)开市起复牌。 截至公告日,交易各方未就本次交易具体方案、交易条件达成最终实质性协议。

50分钟前

汇丰控股:昨日耗资约1.76亿港元回购219.76万股公司股份

36氪获悉,汇丰控股公告,公司于2月4日耗资约1.76亿港元回购219.76万股公司股份,每股回购价格79.6港元-80.45港元。

50分钟前

印尼网约车巨头GoTo否认与Grab合并传闻

印尼网约车巨头GoTo当地时间2月4日提交文件,否认同竞争对手Grab的合并传闻。该公司称,“除实施股票回购外,未来12个月内没有任何重大行动计划”。此前有市场消息称,Grab与GoTo最近几周加快协商,认为今年是达成交易的有利时机。两家公司上市后均逐渐朝向取得盈利迈进,但竞争激烈导致价格无法调涨,同时挤压利润空间。据报道,过去几年双方一直在断断续续地协商,合并障碍包括双方之间的分歧,以及两家公司在印尼、新加坡等市场主导地位可能带来的反垄断问题。(界面)

50分钟前

众鑫股份:泰国工厂一车间正式投产,预计2025年完成产量3万吨以上

36氪获悉,众鑫股份公告,公司泰国工厂一车间已顺利安装完毕,并于2025年1月8号开始调试设备并试机生产,2月1日顺利完成试机并正式投产。同时,二车间开始安装设备。公司预计2025年完成产量3万吨以上,2026年完成产量5万吨。此外,公司将根据国际市场的变化情况,决策是否对泰国工厂实施扩产计划。本次试机成功为公司拓展海外业务打下了基础,也验证了新装备的先进性,为今后的装备研发与升级提供了宝贵经验。

50分钟前

杭州银行:2024年净利润169.83亿元,同比增长18.08%

36氪获悉, 杭州银行发布业绩快报,2024年度实现营业收入383.81亿元,同比增长9.61%;归属于上市公司股东的净利润169.83亿元,同比增长18.08%。截至2024年末,公司总资产21125.91亿元,较上年末增长14.73%;贷款总额9374.99亿元,较上年末增长16.16%;存款总额12725.51亿元,较上年末增长21.74%。

50分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询